20 July 2022 - Approval is supported by efficacy and safety data of two pivotal studies in which Rinvoq demonstrated improvements in disease activity and function.

AbbVie today announced that Health Canada has approved Rinvoq (upadacitinib), the first oral, once daily selective and reversible JAK inhibitor for the treatment of adults with active ankylosing spondylitis who have had an inadequate response to a biologic disease modifying anti-rheumatic drug or when use of those therapies is inadvisable.

Read AbbVie press release